Ex-Pfizer employee, business partner charged with insider trading on COVID drug trial results

  • 📰 FoxBusiness
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 53%

Business News News

Business Business Latest News,Business Business Headlines

A former Pfizer employee and their close friend are facing insider trading charges after federal officials claim they traded on non-public drug trial results in 2021.

After Pfizer CEO Albert Bourla referred to the results as a "game-changer" in the global efforts to end the pandemic, the company's stock rose by nearly 11%. That marked the largest single-day price move in Pfizer's stock since 2009, according to the SEC."Insider trading is not a quick buck. It’s not easy money. It’s not a sure thing. It’s cheating. It’s a bad bet. It’s a ticket to prison," U.S. Attorney Damian Williams said in a statement Thursday.

Pfizer told FOX Business that the company is cooperating with the government's investigation into the matter. "The charges in this case relate to the personal conduct of a former Pfizer employee in violation of the company’s policies," a Pfizer spokesperson told FOX Business. At the time of the trade, Dagar was a senior statistical program lead for the Paxlovid drug trial, which began in July 2021, according to the

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 458. in BUSİNESS

Business Business Latest News, Business Business Headlines